Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CMMB NASDAQ:ICCC NASDAQ:KPTI NASDAQ:PDSB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMMBChemomab Therapeutics$3.09+1.3%$4.03$2.99▼$9.84$14.57M0.51130,510 shs117,082 shsICCCImmuCell$6.33-2.9%$6.43$3.34▼$7.60$57.26M0.297,750 shs1,051 shsKPTIKaryopharm Therapeutics$6.60-2.1%$5.05$3.51▼$16.95$57.23M0.35206,918 shs49,872 shsPDSBPDS Biotechnology$1.20-1.6%$1.21$0.85▼$4.29$56.43M1.15568,471 shs303,726 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMMBChemomab Therapeutics+1.31%-1.59%-21.17%-41.55%-68.08%ICCCImmuCell-2.91%-1.09%+2.43%-3.06%+66.14%KPTIKaryopharm Therapeutics-2.08%-7.17%+63.77%+46.99%-38.26%PDSBPDS Biotechnology-1.64%-3.23%+8.11%-28.99%-60.13%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMMBChemomab Therapeutics$3.09+1.3%$4.03$2.99▼$9.84$14.57M0.51130,510 shs117,082 shsICCCImmuCell$6.33-2.9%$6.43$3.34▼$7.60$57.26M0.297,750 shs1,051 shsKPTIKaryopharm Therapeutics$6.60-2.1%$5.05$3.51▼$16.95$57.23M0.35206,918 shs49,872 shsPDSBPDS Biotechnology$1.20-1.6%$1.21$0.85▼$4.29$56.43M1.15568,471 shs303,726 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMMBChemomab Therapeutics+1.31%-1.59%-21.17%-41.55%-68.08%ICCCImmuCell-2.91%-1.09%+2.43%-3.06%+66.14%KPTIKaryopharm Therapeutics-2.08%-7.17%+63.77%+46.99%-38.26%PDSBPDS Biotechnology-1.64%-3.23%+8.11%-28.99%-60.13%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCMMBChemomab Therapeutics 3.00Buy$26.50757.61% UpsideICCCImmuCell 0.00N/AN/AN/AKPTIKaryopharm Therapeutics 2.80Moderate Buy$34.00415.15% UpsidePDSBPDS Biotechnology 3.00Buy$10.00733.33% UpsideCurrent Analyst Ratings BreakdownLatest CMMB, PDSB, KPTI, and ICCC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/27/2025CMMBChemomab TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$10.00 ➝ $25.008/12/2025KPTIKaryopharm TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$42.00 ➝ $25.007/16/2025KPTIKaryopharm TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral7/11/2025KPTIKaryopharm TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$27.007/1/2025PDSBPDS BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.006/11/2025PDSBPDS BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.00(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCMMBChemomab TherapeuticsN/AN/AN/AN/A$2.87 per shareN/AICCCImmuCell$26.49M2.16$0.06 per share98.45$3.09 per share2.05KPTIKaryopharm Therapeutics$145.24M0.39N/AN/A($22.10) per share-0.30PDSBPDS BiotechnologyN/AN/AN/AN/A$0.51 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCMMBChemomab Therapeutics-$13.94M-$2.36N/AN/AN/AN/A-94.71%-76.53%11/13/2025 (Estimated)ICCCImmuCell-$2.16M$0.1933.32∞N/A6.23%6.25%3.87%11/12/2025 (Estimated)KPTIKaryopharm Therapeutics-$76.42M-$14.59N/AN/AN/A-90.02%N/A-84.28%11/4/2025 (Estimated)PDSBPDS Biotechnology-$37.61M-$0.92N/AN/AN/AN/A-184.56%-79.00%11/13/2025 (Estimated)Latest CMMB, PDSB, KPTI, and ICCC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025CMMBChemomab Therapeutics-$0.80-$0.36+$0.44-$0.09N/AN/A8/14/2025Q2 2025ICCCImmuCellN/A$0.06N/A$0.06N/A$6.45 million8/13/2025Q2 2025PDSBPDS Biotechnology-$0.24-$0.21+$0.03-$0.21N/AN/A8/11/2025Q2 2025KPTIKaryopharm Therapeutics-$3.80-$4.32-$0.52-$4.32$37.92 million$37.93 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCMMBChemomab TherapeuticsN/AN/AN/AN/AN/AICCCImmuCellN/AN/AN/AN/AN/AKPTIKaryopharm TherapeuticsN/AN/AN/AN/AN/APDSBPDS BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCMMBChemomab TherapeuticsN/A7.427.42ICCCImmuCell0.283.851.99KPTIKaryopharm TherapeuticsN/A0.990.94PDSBPDS Biotechnology0.812.922.92Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCMMBChemomab Therapeutics46.05%ICCCImmuCell13.47%KPTIKaryopharm Therapeutics66.44%PDSBPDS Biotechnology26.84%Insider OwnershipCompanyInsider OwnershipCMMBChemomab Therapeutics11.91%ICCCImmuCell5.60%KPTIKaryopharm Therapeutics2.98%PDSBPDS Biotechnology9.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCMMBChemomab Therapeutics204.71 million4.15 millionNot OptionableICCCImmuCell709.05 million8.54 millionNot OptionableKPTIKaryopharm Therapeutics3808.67 million8.41 millionOptionablePDSBPDS Biotechnology2047.03 million42.70 millionOptionableCMMB, PDSB, KPTI, and ICCC HeadlinesRecent News About These CompaniesArmistice Capital LLC Acquires Shares of 4,419,000 PDS Biotechnology Corporation $PDSBSeptember 2, 2025 | marketbeat.comPDS Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 2, 2025 | globenewswire.comPDS Biotechnology Announces Promising Phase 2 Trial ResultsAugust 25, 2025 | msn.comPDS Biotechnology announces data from its VERSATILE-002 Phase 2 trialAugust 25, 2025 | msn.comPDS Biotechnology stock rises after announcing promising cancer trial dataAugust 25, 2025 | za.investing.comPDS Biotechnology Reports 39.3-Month Median Overall Survival in VERSATILE-002 Trial for HPV16-Positive Head and Neck CancerAugust 25, 2025 | quiverquant.comQPDS Biotech Announces Final Topline Survival Data from VERSATILE-002 Phase 2 Trial in Head and Neck CancerAugust 25, 2025 | manilatimes.netMPDS Biotech Announces Final Topline Survival Data from VERSATILE-002 Phase 2 Trial in Head and Neck CancerAugust 25, 2025 | globenewswire.comQ3 EPS Forecast for PDS Biotechnology Boosted by AnalystAugust 17, 2025 | marketbeat.comPDS Biotechnology (NASDAQ:PDSB) Announces Quarterly Earnings ResultsAugust 15, 2025 | marketbeat.comBiotech Stocks Rally as Oncology Market Targets $866B by 2034August 14, 2025 | prnewswire.co.ukPPDS Biotechnology Corporation (NASDAQ:PDSB) Q2 2025 Earnings Call TranscriptAugust 14, 2025 | insidermonkey.comPDS Biotechnology Reports Q2 2025 Financial ResultsAugust 14, 2025 | msn.comPDS Biotechnology Corporation (NASDAQ:PDSB) Q2 2025 Earnings Call TranscriptAugust 14, 2025 | msn.comPDS Biotechnology reports Q2 EPS (21c), consensus (23c)August 13, 2025 | msn.comPDS Biotechnology: Q2 Earnings SnapshotAugust 13, 2025 | stamfordadvocate.comSPDSB Loss Improves as Costs DropAugust 13, 2025 | aol.comAPDS Biotech Reports Second Quarter 2025 Financial Results and Provides Clinical Programs UpdateAugust 13, 2025 | globenewswire.comInsights into PDS Biotechnology's Upcoming EarningsAugust 12, 2025 | benzinga.comPDS Biotechnology (PDSB) Projected to Post Quarterly Earnings on TuesdayAugust 6, 2025 | marketbeat.comPDS Biotech Announces Conference Call and Webcast for Second Quarter 2025 Financial ResultsAugust 6, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCMMB, PDSB, KPTI, and ICCC Company DescriptionsChemomab Therapeutics NASDAQ:CMMB$3.09 +0.04 (+1.31%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$3.09 0.00 (0.00%) As of 09/5/2025 06:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.ImmuCell NASDAQ:ICCC$6.33 -0.19 (-2.91%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$6.43 +0.10 (+1.58%) As of 09/5/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.Karyopharm Therapeutics NASDAQ:KPTI$6.60 -0.14 (-2.08%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$6.50 -0.10 (-1.52%) As of 09/5/2025 06:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.PDS Biotechnology NASDAQ:PDSB$1.20 -0.02 (-1.64%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$1.20 0.00 (-0.42%) As of 09/5/2025 07:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
